Human insulin was the first biopharmaceutical to gain regulatory approval back in 1982, but it is only now that traditional pharmaceuticals are taking a back seat as emerging technologies start to deliver on the promise of providing next generation of medicines.
Most pharmaceutical companies now have dedicated biopharmaceutical or biologics teams – or, at the very least, strategic agreements with smaller biotechnology companies or universities in order to fill their drug pipelines. These new medicines are diverse and can range from blood clotting recombinant proteins to vaccines protecting against cancer. We advise both large and small clients in this area and our life science attorneys not only have wide expertise in biopharmaceuticals, but also pharmaceutical patents so that they can bring together the old and new world to give the best and most up to date advice on this ever changing patent field. We offer a full patent service in this area from patent preparation, prosecution and oppositions – through to obtaining Supplementary Protection Certificates (SPCs) after regulatory approval. Due diligence is also an important element in this area and we frequently advise on freedom to operate, infringement and validity of competitor patents and transactional matters.
The pharmaceutical industry continues to invest heavily in patents to protect their R&D spend in bringing these new medicines to market. Appleyard Lees continues to invest heavily in experienced attorneys and training new attorneys in this area so that you can benefit from up to date advice from people who truly understand your technology.